fda compounding semaglutide enforcement news november 2025 FDA's GLP-1 decision kicks off 'unprecedented' tussle over shortage FDA and Novo Nordisk Warned

For obesity management, NICE has issued relevant guidance and technology appraisals that define NHS eligibility criteria which are distinct from marketing authorisation alone: NICE TA875 covers semaglutide (Wegovy) for managing overweight and obesity, with specific BMI and comorbidity eligibility criteria and requirements for specialist service involvement

Krasner NM, Ido Y, Ruderman NB, et al Glucagonlike peptide1 (GLP1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism

It occurs due to disruption of the normal hair follicle growth cycle

The TRIUMPH-4 data reveal that nearly 1 in 4 patients on the highest dose lost 35% of body weight, not just the average ~28.7%

History of Multiple Drug Allergies People with documented allergies to multiple medications may be more prone to reacting to new compounds